Type 2 immunity in allergic diseases

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells…

• NS
  National Science Foundation
• BS
  Bristol-Myers Squibb
• P
  Pfizer
• A
  AstraZeneca
• G
  GlaxoSmithKline
• S
  Sanofi
• RP
  Regeneron Pharmaceuticals
• IT
  Immune Tolerance Network
• EC
  European Commission
• SN
  Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

  Awards: 310030_189334, 320030E_224154, 310030_189334/1
• MD
  Ministerio de Ciencia e Innovación
• PS
  Promedica Stiftung
• EA
  European Academy of Allergy and Clinical Immunology
• LF
  LEO Fondet
• NI
  National Institutes of Health
• NH
  National Heart, Lung, and Blood Institute
• NI
  National Institute of Allergy and Infectious Diseases
• NI
  National Institute of Environmental Health Sciences